EUVIMEDEUVIMED entdecken
Open Access

Adenosine Receptor 3 Antagonism Suppresses Adipogenesis via the EREG ‐ EGFR ‐Leptin Axis in Multipotent Cells

Chia-Huei Lee, Kuo-Yun Tseng iD, Feng-Huei Lin iD, Hung-Ming Wu, Shankung Lin iD

BioFactors · 2026

DOI: 10.1002/biof.70140 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioFactors, 2026. Verfasst von Chia-Huei Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Cancer Research, National Health Research Institutes, Miaoli, Taiwan. Hauptthemen laut MEDLINE: Adipogenesis, Leptin, Epiregulin, Multipotent Stem Cells. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The role of adenosine receptor 3 (AR3) signaling in adipogenesis remains unclear. Here, we show that AR3 antagonism by MRS1220 inhibited adipogenic differentiation in both C3H10T1/2 and 3T3‐L1 cells, as evidenced by reduced lipid accumulation in both models and suppressed PPARγ2 expression in C3H10T1/2 cells. Transcriptomic profiling and pathway analysis performed in C3H10T1/2 cells suggested that the Ereg gene, which encodes epiregulin (EREG), is a potential target of MRS1220 mediated adipogenesis inhibition. Mechanistically, MRS1220 induced EREG expression, leading to EGFR activation and leptin upregulation, which were critical for its anti‐adipogenic effect. Recombinant EREG mimicked, and EREG neutralization reversed, MRS1220's inhibitory activity. EGFR inhibition abolished MRS1220‐induced leptin expression and restored adipogenesis. Notably, AR3 knockdown abrogated MRS1220's effects on EREG induction, EGFR phosphorylation, leptin induction, and lipid accumulation. In contrast, the AR3 agonist CF101 enhanced adipogenesis independent of the EREG‐EGFR‐leptin axis. These findings establish AR3 as a key regulator of adipogenic differentiation and uncover an AR3‐EREG‐EGFR‐leptin signaling cascade as a mechanism by which AR3 antagonism inhibits adipogenesis. Targeting AR3 may offer a novel strategy to modulate adipose tissue formation in metabolic diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdipogenesisLeptinEpiregulinMultipotent Stem CellsAnimalsErbB ReceptorsMiceSignal Transduction3T3-L1 CellsCell Differentiation

Stichwörter der Autor:innen

adenosine receptor 3adipogenesisepiregulinleptin

Substanzen

ErbB ReceptorsLeptinEpiregulinEGFR protein, mouse

Autor:innen und Institutionen

  • National Institute of Cancer Research, National Health Research Institutes, Miaoli, Taiwan.
  • Taiwan Mycology Reference Center, National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Taiwan.
  • Institute of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University, Taipei, Taiwan.
  • Institute of Biomedical Engineering and Nanomedicine, National Health Research Institutes, Miaoli, Taiwan.
  • Translational Medicine Center, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • Department of Neurology, Chung Shan Medical University, Taichung, Taiwan.

ORCID-Profile: Kuo-Yun Tseng, Feng-Huei Lin, Shankung Lin

Förderung

  • National Science and Technology Council

Zitieren

APA

Lee, C. H., Tseng, K. Y., Lin, F. H., Wu, H. M., & Lin, S. (2026). Adenosine Receptor 3 Antagonism Suppresses Adipogenesis via the EREG ‐ EGFR ‐Leptin Axis in Multipotent Cells. BioFactors. https://doi.org/10.1002/biof.70140

Vancouver

Lee CH, Tseng KY, Lin FH, Wu HM, Lin S. Adenosine Receptor 3 Antagonism Suppresses Adipogenesis via the EREG ‐ EGFR ‐Leptin Axis in Multipotent Cells. BioFactors. 2026. doi:10.1002/biof.70140

BibTeX
@article{Lee2026,
  author = {Lee, Chia-Huei and Tseng, Kuo-Yun and Lin, Feng-Huei and Wu, Hung-Ming and Lin, Shankung},
  title = {Adenosine Receptor 3 Antagonism Suppresses Adipogenesis via the EREG ‐ EGFR ‐Leptin Axis in Multipotent Cells},
  journal = {BioFactors},
  year = {2026},
  doi = {10.1002/biof.70140}
}
Kostenlos starten →